| IPSEN |
IPSEN |
95%
|
In addition, the Ipsen License Agreement provides that we will supply to Ipsen, and Ipsen will purchase from us, all required quantities of tovorafenib for all territories outside the United States i… |
| PHILADELPHIA-LLC-EXPERIC-LLC |
PHILADELPHIA-LLC-EXPERIC-LLC |
85%
|
as well as our commercial products. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, e… |
| STA-PHARMACEUTICAL-HONG-KONG-LIMITED |
STA-PHARMACEUTICAL-HONG-KONG-LIMITED |
85%
|
as well as our commercial products. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, e… |
| CPRX |
Catalyst Pharmaceuticals, Inc. |
72%
|
candidates over alternative treatments; • the cost of treatment in relation to alternative treatments and the cost/benefit ratios of each; • the availability of coverage and adequate reimbursement by… |
| CPRX |
Catalyst Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from CPRX graph: Reciprocal relationship from DAWN graph: Reciprocal relationship from CPRX graph: Reciprocal relationship from DAWN graph: candidates over alternative treatme… |
| GNMSF |
Genmab A/S |
72%
|
Reciprocal relationship from GNMSF graph: Reciprocal relationship from DAWN graph: ual property protections and marketing and selling products for which we may obtain marketing authorization, if any.… |
| GNMSF |
Genmab A/S |
72%
|
ual property protections and marketing and selling products for which we may obtain marketing authorization, if any. We are in the early stages of most of these activities. We may never succeed in th… |
| LLY |
Eli Lilly and Company |
72%
|
ual property protections and marketing and selling products for which we may obtain marketing authorization, if any. We are in the early stages of most of these activities. We may never succeed in th… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from DAWN graph: ual property protections and marketing and selling products for which we may obtain marketing authorization, if any. W… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from DAWN graph: time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the aw… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the awards. • Expected Dividend Yield —The Company has never paid dividends on the common… |
| DANA-FARBER-CANCER-INSTITUTE-MILLENNIUM-PHARMACE |
DANA-FARBER-CANCER-INSTITUTE-MILLENNIUM-PHARMACE |
62%
|
tures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near term or long-term expend… |
| DAY-ONE-BIOPHARMACEUTICALS-HOLDING-COMPANY-LLC |
DAY-ONE-BIOPHARMACEUTICALS-HOLDING-COMPANY-LLC |
62%
|
lthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medi… |
| DAY-ONE-BIOPHARMACEUTICALS-INC |
DAY-ONE-BIOPHARMACEUTICALS-INC |
62%
|
lthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medi… |
| DAY-ONE-THERAPEUTICS-HOLDING-COMPANY-LLC |
DAY-ONE-THERAPEUTICS-HOLDING-COMPANY-LLC |
62%
|
lthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medi… |
| FOUNDATION-MEDICINE-INC |
FOUNDATION-MEDICINE-INC |
62%
|
ined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance… |
| HERO-THERAPEUTICS-HOLDING-COMPANY-LLC |
HERO-THERAPEUTICS-HOLDING-COMPANY-LLC |
62%
|
lthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medi… |
| IPSEN-BIOPHARMACEUTICALS-INC |
IPSEN-BIOPHARMACEUTICALS-INC |
62%
|
t the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current l… |
| JAZZ |
Jazz Pharmaceuticals plc |
62%
|
Reciprocal relationship from JAZZ graph: Reciprocal relationship from DAWN graph: candidates over alternative treatments; • the cost of treatment in relation to alternative treatments and the cost/be… |
| JAZZ-PHARMACEUTICALS-INC |
JAZZ-PHARMACEUTICALS-INC |
62%
|
candidates over alternative treatments; • the cost of treatment in relation to alternative treatments and the cost/benefit ratios of each; • the availability of coverage and adequate reimbursement by… |
| MERSANA-THERAPEUTICS-INC |
MERSANA-THERAPEUTICS-INC |
62%
|
ember 31, 2025 , 2024, and 2023, the Company made matching contributions of $ 1.9 million, $ 1.7 million, and $ 1.3 million, respectively. 14. Segment Reporting The Company views its operations and m… |
| MILLENNIUM-PHARMACEUTICALS-INC |
MILLENNIUM-PHARMACEUTICALS-INC |
62%
|
time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the awards. • Expected Dividend Yield —The Company has never paid dividends on the common… |
| ONCOLOGY-GROUP |
ONCOLOGY-GROUP |
62%
|
authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdicti… |
| PHILADELPHIA-LLC |
PHILADELPHIA-LLC |
62%
|
tion. The Company identified two distinct performance obligations for licenses to intellectual property in the form of the exclusive license to commercialize tovorafenib outside the United States for… |
| SUNESIS-PHARMACEUTICALS-INC |
SUNESIS-PHARMACEUTICALS-INC |
62%
|
on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would redu… |
| TAKEDA-PHARMACEUTICAL-COMPANY-LIMITED-VIRACTA-TH |
TAKEDA-PHARMACEUTICAL-COMPANY-LIMITED-VIRACTA-TH |
62%
|
event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure such as our research facilities or the manufacturing facilities of o… |
| US-LLC |
US-LLC |
62%
|
2024, the Company entered into an amendment to the Viracta License Agreement. As part of the amendment, the Company made a one-time payment in March 2024 to Viracta of $ 5.0 million, which was record… |
| VIRACTA-THERAPEUTICS-INC |
VIRACTA-THERAPEUTICS-INC |
62%
|
on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would redu… |
| VIRACTA-THERAPEUTICS-INC-TAKEDA-PHARMACEUTICAL-C |
VIRACTA-THERAPEUTICS-INC-TAKEDA-PHARMACEUTICAL-C |
62%
|
nuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, operating results, financial condi… |
